News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
184,480 Results
Type
Article (17685)
Company Profile (120)
Press Release (166675)
Section
Business (58564)
Career Advice (944)
Deals (9408)
Drug Delivery (36)
Drug Development (23547)
Employer Resources (72)
FDA (2403)
Job Trends (4278)
News (92830)
Policy (5846)
Tag
2024 BioCapital Digital (3)
2024 BioMidwest Digital (4)
2024 Bio NC Digital (5)
2024 Bio NC Standard (2)
2024 Biotech Bay Standard (10)
2024 Biotech Beach Digital (8)
2024 Biotech Beach Standard (5)
2024 Genetown Digital (7)
2024 Genetown Standard (6)
2024 Lone Star Bio Digital (2)
2024 Pharm Country Digital (4)
2024 Pharm Country Standard (3)
2025 Lone Star Bio Digital (1)
2026 BioMidwest Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (1)
Academia (487)
Accelerated approval (1)
Adcomms (13)
Allergies (19)
Alliances (16321)
ALS (34)
Alzheimer's disease (435)
Antibody-drug conjugate (ADC) (77)
Approvals (2369)
Artificial intelligence (99)
Autoimmune disease (9)
Automation (4)
Bankruptcy (82)
Best Places to Work (2927)
BIOSECURE Act (18)
Biosimilars (26)
Biotechnology (111)
Bladder cancer (25)
Brain cancer (14)
Breast cancer (81)
Cancer (792)
Cardiovascular disease (56)
Career advice (761)
Career pathing (20)
CAR-T (94)
Cell therapy (256)
Cervical cancer (7)
Clinical research (18729)
Collaboration (404)
Compensation (96)
Complete response letters (11)
COVID-19 (748)
CRISPR (17)
C-suite (129)
Cystic fibrosis (40)
Data (668)
Denatured (5)
Depression (19)
Diabetes (61)
Diagnostics (1084)
Digital health (2)
Diversity (2)
Diversity, equity & inclusion (21)
Drug discovery (63)
Drug pricing (23)
Drug shortages (2)
Duchenne muscular dystrophy (37)
Earnings (16019)
Editorial (17)
Employer branding (8)
Employer resources (69)
Events (31498)
Executive appointments (342)
FDA (2691)
Featured Employer (22)
Friedreich's ataxia (2)
Frontotemporal dementia (6)
Funding (348)
Gene editing (50)
Generative AI (12)
Gene therapy (177)
GLP-1 (270)
Government (632)
Grass and pollen (1)
Guidances (9)
Healthcare (2439)
Huntington's disease (18)
IgA nephropathy (11)
Immunology and inflammation (65)
Indications (11)
Infectious disease (802)
Inflammatory bowel disease (69)
Inflation Reduction Act (3)
Influenza (20)
Intellectual property (42)
Interviews (139)
IPO (4130)
IRA (13)
Job creations (1476)
Job search strategy (703)
Kidney cancer (4)
Labor market (22)
Layoffs (165)
Leadership (11)
Legal (1195)
Liver cancer (17)
Lung cancer (91)
Lymphoma (57)
Machine learning (2)
Management (23)
Manufacturing (137)
MASH (21)
Medical device (774)
Medtech (775)
Mergers & acquisitions (5476)
Metabolic disorders (225)
Multiple sclerosis (30)
NASH (8)
Neurodegenerative disease (46)
Neuropsychiatric disorders (13)
Neuroscience (643)
NextGen: Class of 2025 (1460)
Non-profit (476)
Northern California (871)
Now hiring (16)
Obesity (128)
Opinion (175)
Ovarian cancer (33)
Pain (29)
Pancreatic cancer (26)
Parkinson's disease (48)
Partnered (9)
Patents (73)
Patient recruitment (30)
Peanut (12)
People (22190)
Pharmaceutical (15)
Phase I (7266)
Phase II (8933)
Phase III (5047)
Pipeline (404)
Podcasts (30)
Policy (55)
Postmarket research (312)
Preclinical (2953)
Press Release (61)
Prostate cancer (29)
Psychedelics (18)
Radiopharmaceuticals (83)
Rare diseases (168)
Real estate (2452)
Recruiting (36)
Regulatory (4555)
Reports (20)
Research institute (517)
Resumes & cover letters (152)
RNA editing (2)
RSV (13)
Schizophrenia (23)
Series A (80)
Series B (43)
Service/supplier (6)
Sickle cell disease (22)
Southern California (804)
Special edition (10)
Spinal muscular atrophy (48)
Sponsored (11)
Startups (1788)
State (1)
Stomach cancer (5)
Supply chain (21)
The Weekly (25)
United States (7194)
Vaccines (224)
Venture capitalists (32)
Webinars (9)
Weight loss (87)
Women's health (9)
Worklife (7)
Date
Today (57)
Last 7 days (215)
Last 30 days (1105)
Last 365 days (12436)
2025 (2818)
2024 (12719)
2023 (13269)
2022 (16165)
2021 (17027)
2020 (13312)
2019 (9589)
2018 (7626)
2017 (9040)
2016 (8174)
2015 (9480)
2014 (9802)
2013 (9515)
2012 (6147)
2011 (6492)
2010 (5869)
Location
Africa (331)
Alabama (27)
Alaska (3)
Arizona (45)
Arkansas (2)
Asia (13587)
Australia (2782)
California (2044)
Canada (676)
China (180)
Colorado (38)
Connecticut (82)
Delaware (35)
Europe (30348)
Florida (221)
Georgia (33)
Idaho (13)
Illinois (128)
India (10)
Indiana (103)
Iowa (3)
Japan (53)
Kansas (16)
Kentucky (4)
Louisiana (3)
Maine (2)
Maryland (311)
Massachusetts (1597)
Michigan (74)
Minnesota (117)
Missouri (21)
Montana (8)
Nebraska (4)
Nevada (10)
New Hampshire (6)
New Jersey (543)
New Mexico (11)
New York (524)
North Carolina (347)
North Dakota (4)
Northern California (871)
Ohio (57)
Oklahoma (7)
Oregon (8)
Pennsylvania (427)
Puerto Rico (3)
Rhode Island (8)
South America (403)
South Carolina (2)
Southern California (804)
Tennessee (19)
Texas (238)
Utah (30)
Virginia (14)
Washington D.C. (17)
Washington State (320)
Wisconsin (11)
184,480 Results for "viva biotech".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Viva Biotech (1873.HK) Announces 2023 Annual Results: Successful Implementation of Light-asset Strategy, Achieving Solid Growth and Promising Future
On March 28, 2024, Viva Biotech Holdings Group announced that the Group’s revenue during the Reporting Period achieved RMB2,155.6 million; and our gross profit amounted to RMB738.5 million.
March 28, 2024
·
17 min read
Viva Biotech Secures Approximately US$ 210 Million Funding
On November 20, 2023 , Viva Biotech Holdings Group (1873. HK) announced that it completed a funding round, securing approximately US$210 million and bringing in the strategic investors, Temasek, Highlight Capital (HLC), and True Light.
November 20, 2023
·
3 min read
Business
Viva Biotech Announces Its 2024 Interim Results: Significant Improvement in Net Profit Growth and Ongoing Optimization of Emerging Technology Platforms
August 29, 2024
·
17 min read
Viva Biotech Announced Strategic Investors with an Investment of Approximately US$ 210 Million
On June 11, 2023, Viva Biotech Holdings Group announced that Viva Shanghai, the primary entity for Viva Biotech’s CRO business, successfully raised nearly US$ 150 million through the transfer of approximately 24% of its equity interest to Temasek, HLC, and True Light.
June 16, 2023
·
4 min read
Executive appointments
Women Leaders Decline in Biotech’s Era of ‘Proven Leadership’
Of the 102 company launches or series A financings since October 2023, just nine had a woman at the helm, according to a
BioSpace
analysis. This is happening in an era of biotech where new company founders are searching for CEOs with a track record.
February 5, 2025
·
8 min read
·
Annalee Armstrong
C-suite
Biotech a Bright Spot for Female Founders Amid DEI Pullback
A new Pitchbook report found $4.3 billion in funding to women-fronted biotech companies across 121 deals. The increase comes as sociopolitical headwinds slam into initiatives to support women and minorities.
March 6, 2025
·
2 min read
·
Annalee Armstrong
Bankruptcy
Bluebird’s Go-Private Deal Highlights Fraught Life Preserver for Struggling Biotechs
Facing declining valuations and funding challenges, public biotechs like bluebird bio are going private to restructure, reduce regulatory burdens and refocus on long-term growth.
March 12, 2025
·
6 min read
·
Ana Mulero
Latest Updates of Viva Biotech’s Portfolio Companies
Even with the ever-changing situation, technological innovation is still the most critical component for biopharmaceutical companies’ long-term development.
March 6, 2024
·
9 min read
Legal
Novo Seeks $830M in Fraud Case Against Singaporean Biotech Over Kidney Drug
Back in 2023, Novo Nordisk committed up to $1.3 billion for a hypertension and kidney disease drug from KBP Biosciences. Now, the pharma giant claims to have been misled by the biotech’s founder—and a judge seems to agree.
February 18, 2025
·
1 min read
·
Annalee Armstrong
Business
Viva Biotech’s Portfolio Company Riparian Pharmaceuticals Announces Exclusive License Agreement and Research Agreement with Pfizer for Novel Cardiovascular Programs
Riparian Pharmaceuticals, a Viva Biotech portfolio company, is a biotechnology company focused on discovering novel therapeutics for cardiovascular diseases.
July 20, 2023
·
3 min read
1 of 18,448
Next
